-
Products are supplied strictly for laboratory and scientific research — not for human or veterinary use.
CJC-1295 and ipamorelin are frequently mentioned together, but they are different experimental peptides that interact with different signaling systems.
CJC-1295 is a growth-hormone-releasing hormone analogue studied for its influence on growth-hormone signaling. Ipamorelin is a growth-hormone secretagogue associated with the ghrelin receptor. Studying two pathways together does not make the compounds equivalent or prove a therapeutic benefit.
Researchers may be interested in how separate receptor pathways affect pulsatile hormone release and downstream biomarkers. Outcomes depend on the exact molecule, formulation, model and experimental design. CJC-1295 variants should also be named precisely because modifications can change pharmacokinetic behavior.
Early human studies have examined certain biomarkers, but evidence is not sufficient for the broad sleep, muscle, fat-loss or anti-aging claims common online. Neither product should be marketed as an approved treatment for those purposes.
FDA has flagged potential safety concerns involving compounded CJC-1295 and certain ipamorelin routes, including immunogenicity, impurities and limited safety information. Compounded drugs are not FDA-approved.
No. They have different structures and receptor targets.
No. A combination requires its own evidence and introduces more experimental variables.
No.
Research catalog CTA: Compare CJC-1295 and ipamorelin research specifications in the GenLab Meds catalog. Not for human or veterinary use.
Authoritative source: FDA bulk-substance safety information: Authoritative source
